Incorrect password
evipedia.ai Suggest Edit

Fisetin as a Senolytic Therapy

Evidence Review created on 04/22/2026 using AI4L / Opus 4.7

Also known as: 3,3’,4’,7-Tetrahydroxyflavone, 7,3’,4’-Flavon-3-ol

Motivation

Fisetin is a plant flavonoid — a naturally occurring pigment found in small amounts in strawberries, apples, persimmons, and certain tree woods — that has drawn intense interest as a candidate senolytic. Senolytics are compounds that selectively clear senescent (“zombie”) cells, which accumulate with age, resist normal cell death, and secrete inflammatory signals thought to accelerate tissue decline. Clearing these cells has emerged as a leading strategy for extending healthspan.

Although fisetin has been studied for decades as an antioxidant and neuroprotective flavonoid, attention to its senolytic potential was catalyzed by early mouse work identifying it among the most active flavonoids in clearing senescent cells. A subsequent multi-site mouse replication effort did not reproduce the earlier lifespan signal, and no large human trial has yet confirmed senolytic clearance in humans — leaving the field in an unusual state where enthusiasm, mechanism, and skepticism all coexist, and where a growing clinical-trial pipeline is expected to resolve the open questions.

This review examines the evidence for fisetin as a senolytic intervention in adults seeking to extend healthspan — covering mechanism, benefits, risks, protocol, sourcing, and the expanding clinical-trial pipeline — and notes where the evidence is strong, weak, or actively disputed.

Benefits - Risks - Protocol - Conclusion

This section presents curated high-quality resources that provide accessible, substantive overviews of fisetin’s senolytic activity and its place in the broader longevity toolkit.

  • Fisetin: A Senolytic That Extends Life - Charles Wyatt

    Narrative overview of fisetin’s senolytic mechanism, the Yousefzadeh mouse lifespan study, bioavailability limitations of unformulated fisetin, and the development of galactomannan-enhanced formulations. A clear starting point for understanding why fisetin became a focus of senolytic interest.

  • Fisetin inhibits senescence and slows down aging - Rhonda Patrick

    Concise FoundMyFitness news summary of the key senescence research on fisetin, linking the primary literature and situating fisetin within the broader emerging field of senolytics and cellular-senescence biology.

  • #112 – Ned David, Ph.D.: How cellular senescence influences aging, and what we can do about it - Peter Attia

    Long-form interview with a co-founder of Unity Biotechnology covering the biology of cellular senescence, the senescence-associated secretory phenotype, and senolytic drug development — essential context for the mechanistic claims made about fisetin.

  • Fisetin & Your Brain - Alzheimer’s Drug Discovery Foundation

    Independent expert assessment of fisetin’s neuroprotective and cognitive-support evidence, written for a general audience. Notable for its honest evaluation of the gap between animal data and human evidence and its discussion of safety considerations.

  • Fisetin Is a Senotherapeutic That Extends Health and Lifespan - Yousefzadeh et al., 2018

    The landmark EBioMedicine primary-research paper that identified fisetin as the most potent of ten flavonoids tested for senolytic activity and reported extension of lifespan in naturally aged mice. Any serious discussion of fisetin as a senolytic begins with this study.

No directly relevant content covering fisetin as a senolytic was located from Andrew Huberman (hubermanlab.com) or Chris Kresser (chriskresser.com) as of 04/22/2026; both experts discuss adjacent topics (autophagy, polyphenols, aging biology) but neither appears to have published a focused piece on fisetin.

Grokipedia

Fisetin

Grokipedia’s dedicated article on fisetin covers its chemical identity (molecular formula C₁₅H₁₀O₆), dietary sources, biological activities, and growing body of senolytic research, including a discussion of the Mayo Clinic mouse work and subsequent human clinical-trial landscape.

Examine

No dedicated Examine.com article for fisetin exists as of 04/22/2026.

ConsumerLab

Can Fisetin (Also Called Cognisetin and Novusetin) Really Improve Memory?

ConsumerLab’s cautious assessment notes that fisetin’s cell and animal data are intriguing but human evidence is thin, and that it is premature to conclude fisetin is safe and effective for memory or any other indication in people. The page also covers the Salk Institute patent on fisetin for cognitive enhancement.

Systematic Reviews

This section presents the most relevant systematic reviews and meta-analyses indexed on PubMed bearing on fisetin’s evidence base, with emphasis on outcomes adjacent to the senolytic thesis.

Mechanism of Action

Fisetin’s proposed senolytic activity arises from a multi-target profile that selectively pushes senescent cells toward apoptosis (programmed cell death) while largely sparing healthy cells. The principal pathways are:

  • Inhibition of anti-apoptotic proteins: Fisetin downregulates BCL-2 (B-cell lymphoma 2, an anti-apoptotic protein) and BCL-XL (B-cell lymphoma extra-large, a related survival protein), two proteins that senescent cells rely on to resist normal cell-death signals. Blocking these survival proteins allows the intrinsic apoptosis machinery to eliminate senescent cells.
  • PI3K/AKT/mTOR pathway suppression: Fisetin inhibits the PI3K (phosphoinositide 3-kinase, a lipid-signaling kinase) / AKT (protein kinase B, a pro-survival kinase) / mTOR (mechanistic target of rapamycin, a master growth and nutrient-sensing regulator) signaling cascade, on which senescent cells are especially dependent for persistence.
  • NF-κB inhibition: Fisetin suppresses NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a central regulator of inflammation), directly reducing the production of SASP (senescence-associated secretory phenotype, the mix of inflammatory cytokines and proteases secreted by senescent cells) components including IL-6 (interleukin-6, an inflammatory cytokine), TNF-α (tumor necrosis factor-alpha, a pro-inflammatory cytokine), and MCP-1 (monocyte chemoattractant protein-1, an immune-cell-recruiting chemokine).
  • Antioxidant activity and Nrf2 activation: Fisetin scavenges ROS (reactive oxygen species, chemically reactive molecules that damage cellular components) and upregulates the Nrf2 (nuclear factor erythroid 2-related factor 2, a master regulator of antioxidant gene expression) pathway, increasing intracellular glutathione (the cell’s major endogenous antioxidant) and reducing the oxidative stress that both triggers and sustains senescence.
  • Sirtuin activation: Fisetin activates SIRT1 (sirtuin 1, a longevity-associated NAD⁺-dependent deacetylase) and has been reported to modulate AMPK (AMP-activated protein kinase, a cellular energy sensor), linking it to canonical longevity signaling.

A mechanistic alternative view — often called a “senomorphic” interpretation — holds that at typical oral exposures in humans, fisetin may primarily blunt the inflammatory SASP signal from senescent cells rather than truly killing them. This framing has gained traction following the negative Interventions Testing Program lifespan study and unresolved questions about whether unformulated oral fisetin reaches tissue concentrations sufficient for direct senolysis.

Fisetin is a pharmacologically active small molecule (molecular weight 286.24 g/mol). Its key pharmacological properties are:

  • Half-life: Approximately 1–3 hours for the parent compound in plasma; metabolites (glucuronides, sulfates, methylated forms) persist longer.
  • Selectivity: Broad-target polyphenol with no single high-affinity receptor; selectivity for senescent over healthy cells is thought to arise from the distinct dependence of senescent cells on BCL-2/BCL-XL and PI3K/AKT for survival.
  • Tissue distribution: Widely distributed after absorption, with detectable levels in brain, liver, kidney, adipose tissue, and cartilage in animal studies; poor aqueous solubility constrains native oral bioavailability.
  • Metabolism: Extensive gut and hepatic metabolism, primarily via glucuronidation (UGT1A isoforms), sulfation (SULT enzymes, sulfotransferases that attach sulfate groups to polyphenols for elimination), and O-methylation (COMT, catechol-O-methyltransferase). Phase I oxidation via CYP (cytochrome P450) enzymes (notably CYP3A4, CYP1A2, CYP2C9) is secondary but clinically relevant for drug interactions.

Historical Context & Evolution

Fisetin was first isolated in the 19th century from the heartwood of the smoke tree (Cotinus coggygria, formerly classified as Rhus cotinus), where it was long used as a natural yellow textile dye. Its name derives from the German “Fisettholz” (young fustic wood). For roughly a century, fisetin was studied almost exclusively as a plant pigment rather than a bioactive compound.

Biological interest in fisetin grew in the 1990s and 2000s, when Pamela Maher and colleagues at the Salk Institute identified fisetin as a neuroprotective flavonoid that enhanced long-term memory in mice and reduced markers of Alzheimer-type pathology in disease models. Over the next decade, fisetin was characterized as an antioxidant, an anti-inflammatory agent, and an anticancer flavonoid across multiple in vitro and animal systems.

The pivotal reframing of fisetin as a senolytic came in 2018, when a team led by James Kirkland and Laura Niedernhofer, working with the Mayo Clinic and the University of Minnesota, screened ten flavonoids for senolytic activity in cell culture and aged-mouse models. They reported that fisetin was the most potent of the compounds tested, reduced senescence markers across multiple tissues in progeroid and naturally aged mice, and — when begun late in life — extended median and maximum lifespan by roughly 10%. This paper rapidly repositioned fisetin from a modest dietary flavonoid into a leading candidate senolytic and catalyzed a wave of human clinical trials. It should be noted that the Mayo Clinic/University of Minnesota groups that produced this foundational finding have ongoing institutional programs and grant funding tied to senolytic development (including subsequent Mayo-led human trials), which is a structural conflict of interest to keep in mind when weighing the primary positive evidence.

Scientific opinion has not converged on a final reading. A high-rigor 2023 study from the Interventions Testing Program — a multi-site, genetically heterogeneous UM-HET3 mouse program funded by the National Institute on Aging to evaluate candidate longevity interventions — reported no significant lifespan effect of fisetin at the dose and schedule tested. This failure to replicate, rather than a resolution in either direction, is what currently defines the state of the field: the 2018 result has not been formally retracted, the 2023 result has not been formally refuted, and plausible explanations (strain background, dose, formulation, timing, bioavailability) remain under active investigation.

Expected Benefits

A dedicated search for fisetin’s benefit profile was performed using PubMed, clinicaltrials.gov, drug-reference sources, and expert commentary before writing this section.

Medium 🟩 🟩

Reduction of Senescent Cell Burden and SASP Signalling

Fisetin selectively promotes apoptosis of senescent cells via BCL-2/BCL-XL inhibition and PI3K/AKT/mTOR suppression, and independently suppresses NF-κB-driven production of IL-6, TNF-α, and MCP-1. In the Yousefzadeh 2018 mouse work, fisetin reduced markers of senescence — SA-β-gal (senescence-associated beta-galactosidase, a lysosomal enzyme enriched in senescent cells), p16INK4a (cyclin-dependent kinase inhibitor 2A, a senescence marker), and p21 (cyclin-dependent kinase inhibitor 1A, a cell-cycle arrest protein) — across adipose, liver, and kidney tissue. Early human pilot data from the COVFIS and Mayo Clinic skeletal trials have reported measurable reductions in circulating SASP markers after short-course oral fisetin, though the effect size and durability in humans remain to be fully characterized.

Magnitude: In aged-mouse tissues, approximately 50–70% reduction in SA-β-gal-positive cells after a 5-day feeding of fisetin; human reductions in circulating IL-6 and TNF-α in small pilot studies are in the range of 15–40% from baseline.

Anti-Inflammatory Effects

Independent of senolysis, fisetin directly inhibits NF-κB activation and suppresses production of pro-inflammatory cytokines. In animal models and human cells, fisetin attenuates TLR (Toll-like receptor, a pattern-recognition innate-immune receptor)-driven inflammatory signalling and reduces tissue infiltration by inflammatory macrophages.

Magnitude: Approximately 40–60% reduction in NF-κB activation in cell culture; reductions in IL-6 and TNF-α in the 20–50% range across multiple animal models.

Antioxidant Effects and Glutathione Support

Fisetin scavenges ROS directly and activates Nrf2, upregulating endogenous antioxidant defences including glutathione synthesis and detoxifying phase II enzymes.

Magnitude: Approximately 30–50% increase in intracellular glutathione in treated cell and animal systems; ROS-scavenging potency in vitro is comparable to quercetin on a molar basis.

Low 🟩

Neuroprotection and Cognitive Support

Animal studies — substantially from the Salk group — show that fisetin prevents amyloid-beta-induced memory deficits, reduces tau hyperphosphorylation, and promotes BDNF (brain-derived neurotrophic factor, a key neuronal growth factor) expression. Several transgenic Alzheimer models show attenuation of neuropathology with chronic fisetin exposure. No completed randomised trial has confirmed cognitive benefit in humans.

Magnitude: Prevention of memory deficits in amyloid-beta-injected mouse models; roughly 25–40% reduction in tau hyperphosphorylation markers in Alzheimer’s disease mouse models.

Bone and Joint Health

Fisetin reduces senescent-chondrocyte burden and cartilage degradation in animal osteoarthritis models, and is being actively evaluated in human trials for knee osteoarthritis and skeletal health in older adults. The Yamaura 2022 systematic review supports a chondroprotective signal in preclinical data.

Magnitude: Reductions in cartilage degeneration scores and in senescent-chondrocyte burden in rodent osteoarthritis models; human magnitude not yet quantified.

Cardiovascular and Vascular Function

Preclinical evidence suggests fisetin improves endothelial function, reduces arterial stiffness markers, and attenuates ischemia-reperfusion injury. The Prem 2022 and Adeli 2024 systematic reviews summarise this literature. A human trial (NCT06133634) is evaluating vascular endpoints in older adults.

Magnitude: Not quantified in available studies.

Anticancer Signals

Fisetin shows anti-proliferative and pro-apoptotic activity across prostate, breast, colon, and lung cancer cell lines, with mechanisms including cell-cycle arrest, inhibition of angiogenesis, and modulation of autophagy. Evidence is essentially preclinical, with no confirmatory human trials reporting a clinical anticancer benefit.

Magnitude: In vitro IC50 (concentration producing 50% inhibition of cell proliferation) values of approximately 10–100 μM across various cancer cell lines; animal tumour-growth reductions are variable by model.

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

The 2018 Yousefzadeh mouse study reported approximately 10% extension of median and maximum lifespan with late-life fisetin. The 2023 Interventions Testing Program study in UM-HET3 mice (Harrison et al.) reported no significant lifespan extension at the doses and schedule tested. The discrepancy may reflect strain background, formulation and bioavailability, dosing schedule, or cohort timing. The lifespan claim therefore sits at the boundary of “promising” and “not replicated,” and is explicitly flagged as conflicted.

Metabolic and Adipose Benefits

Preclinical data suggest fisetin may improve insulin sensitivity, reduce adipogenesis (fat-cell formation), and attenuate diet-induced obesity in rodents, potentially through AMPK activation and senolytic clearance of senescent preadipocytes. Human data are not yet available.

Skin Senescence and Dermal Ageing

Topical and systemic fisetin has shown ability to reduce UV (ultraviolet light)-induced senescence markers and photoaging signs in skin cell and animal models. No controlled human trials of topical or oral fisetin for dermal aging endpoints have been reported.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in UGT1A (UDP-glucuronosyltransferase 1A family, phase II enzymes responsible for glucuronidation of many flavonoids), SULT1A1 (sulfotransferase 1A1, a phase II enzyme), and COMT can substantially alter fisetin clearance and therefore tissue exposure. ABCB1 (ATP-binding cassette sub-family B member 1, encoding the P-glycoprotein drug efflux pump) variants influence absorption and blood-brain-barrier penetration. Slow-metabolizer phenotypes are expected to yield higher exposure at a given dose and potentially greater benefit — and greater side-effect risk.
  • Baseline biomarker levels: Adults with higher baseline systemic inflammation (elevated hs-CRP (high-sensitivity C-reactive protein, a general marker of systemic inflammation), IL-6) and with markers of higher senescent-cell burden are more likely to derive measurable benefit from senolytic-schedule fisetin. Individuals with already-optimal inflammation markers are less likely to see a discernible effect.
  • Sex-based differences: No robust human sex-based differences in fisetin’s senolytic efficacy have been identified. The 2023 Interventions Testing Program mouse study reported no significant lifespan effect in either male or female UM-HET3 mice.
  • Pre-existing health conditions: Conditions associated with accelerated cellular senescence — type 2 diabetes, obesity, osteoarthritis, idiopathic pulmonary fibrosis (a progressive scarring disease of the lungs of unknown cause), chronic kidney disease, and prior chemotherapy or radiation exposure — represent populations in which senolytic benefit is most plausible and in which the active trials are enrolling.
  • Age-related considerations: Senescent-cell burden rises with chronological age, so older adults (particularly over age 60) are the population with the largest plausible benefit. Adults over 75 may also have reduced hepatic and renal clearance, which can increase exposure at a given dose and shifts the benefit–risk calculation.

Potential Risks & Side Effects

A dedicated search for fisetin’s side-effect profile was performed using PubMed, clinical-trial registries, drugs.com, prescribing-adjacent references for quercetin as a structurally similar flavonoid, and expert commentary before writing this section.

Medium 🟥 🟥

Gastrointestinal Discomfort

Mild-to-moderate nausea, abdominal discomfort, loose stools, and occasional diarrhea are the most commonly reported adverse events at the high doses used in senolytic protocols (20 mg/kg/day). Symptoms are typically transient and resolve after the 2–3 day dosing window closes. Lower daily doses (100–500 mg) are rarely associated with GI (gastrointestinal) symptoms.

Magnitude: Approximately 10–20% incidence of mild GI symptoms in the high-dose senolytic clinical-trial population; typically self-limiting within 24–48 hours.

Low 🟥

Drug-Drug Interactions via Cytochrome P450 Inhibition

Fisetin inhibits CYP3A4 (cytochrome P450 3A4, the most common hepatic drug-metabolising enzyme) and CYP2C9 (cytochrome P450 2C9, the enzyme metabolising warfarin and several non-steroidal anti-inflammatory drugs) in vitro, and at senolytic doses may clinically elevate plasma levels of co-administered substrates of these enzymes. Fisetin is also a weak UGT inhibitor.

Magnitude: Not quantified in available studies.

Poor Oral Bioavailability of Unformulated Fisetin

Unformulated crystalline fisetin has very low oral bioavailability due to poor aqueous solubility, rapid gut and hepatic glucuronidation and sulfation, and extensive first-pass metabolism. The clinical risk is not toxicity but ineffective therapy: many consumers may be taking doses insufficient to achieve senolytic tissue concentrations.

Magnitude: Oral bioavailability of unformulated fisetin is estimated at approximately 3–10%; galactomannan-based formulations have reported approximately 25-fold improvement in a human pharmacokinetic study (Krishnakumar et al., 2022, PMID 36304817).

Antiplatelet and Anticoagulant Potentiation

Fisetin inhibits platelet aggregation in vitro and may additively potentiate the effects of anticoagulant and antiplatelet medications. No clinically significant bleeding has been attributed to fisetin in published trials, but the theoretical interaction is biologically plausible and relevant before surgery and in those on warfarin, direct oral anticoagulants, or antiplatelet therapy.

Magnitude: Not quantified in available studies.

Speculative 🟨

Impairment of Physiological Senescence Functions

Senescent cells have transient, beneficial roles in wound healing, tissue remodelling, and embryonic development. Aggressive or poorly timed senolytic dosing could in principle impair wound healing or post-injury tissue repair. No clinical signal of this in fisetin trials to date, but it is a theoretical consideration during acute injury or post-surgical recovery.

Theoretical Effects on Tumour Surveillance and Immunity

Cellular senescence participates in tumour suppression by arresting damaged cells and in certain immune responses. Broad senolytic therapy could in principle compromise these protective functions. No clinical data to support this concern for fisetin specifically, but it is why active malignancy is typically treated as a relative contraindication outside a clinical-trial context.

Dose-Dependent Pro-Oxidant or Genotoxic Effects at Supraphysiologic Exposure

Like many polyphenols, fisetin shows pro-oxidant and mildly genotoxic effects in vitro at very high concentrations. The Alzheimer’s Drug Discovery Foundation’s assessment notes this has been identified in some experimental contexts. No corresponding signal has been reported in animal or human studies at therapeutic oral doses.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP3A4 and CYP2C9 poor-metabolizer phenotypes may elevate fisetin plasma levels at a given dose and increase the likelihood of drug-drug interactions. UGT1A1 variants — including those that underlie Gilbert syndrome (a common, benign genetic condition of mildly elevated bilirubin) — may slow fisetin clearance. ABCB1 variants alter tissue distribution.
  • Baseline biomarker levels: Elevated baseline liver enzymes (ALT (alanine aminotransferase), AST (aspartate aminotransferase)) warrant caution with high-dose senolytic protocols, since fisetin undergoes extensive hepatic metabolism. Elevated baseline creatinine or reduced eGFR (estimated glomerular filtration rate, a measure of kidney function) should prompt dose reduction and closer monitoring.
  • Sex-based differences: No sex-specific risk differences have been identified in published fisetin trials or systematic reviews.
  • Pre-existing health conditions: Bleeding disorders, anticoagulant or antiplatelet therapy, severe hepatic impairment, severe renal impairment, active malignancy, and recent or planned surgery (within 7–14 days) all increase risk. Pregnancy and lactation are de facto contraindications due to absent safety data.
  • Age-related considerations: Adults over approximately 75 may have reduced hepatic and renal clearance, leading to higher effective plasma exposure. Polypharmacy is more prevalent in this group, increasing the probability of a clinically relevant CYP-mediated interaction.

Key Interactions & Contraindications

  • Prescription drug interactions: Anticoagulants (warfarin, direct oral anticoagulants such as apixaban, rivaroxaban, dabigatran — additive bleeding risk, plus CYP2C9 interaction with warfarin); CYP3A4-metabolised statins (atorvastatin, simvastatin — potential increased statin exposure); calcium channel blockers (amlodipine, diltiazem, verapamil — CYP3A4 interaction); immunosuppressants (cyclosporine, tacrolimus — CYP3A4 interaction with narrow therapeutic index); and certain cytotoxic chemotherapy agents (potential altered exposure). Severity: caution for most, with close monitoring or avoidance; for narrow-therapeutic-index CYP3A4 substrates such as tacrolimus, absolute avoidance outside clinical supervision is advisable.
  • Over-the-counter medication interactions: Non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen (additive GI and bleeding risk); aspirin (additive antiplatelet effect); acetaminophen at high doses (potential competition for glucuronidation pathways). Severity: generally caution-level.
  • Supplement interactions: Quercetin (additive senolytic activity — desirable in combination protocols, but increases total senolytic load); curcumin/turmeric (CYP3A4 inhibition that can further elevate fisetin exposure); fish oil/omega-3 supplements (additive antiplatelet effect); resveratrol (overlapping sirtuin-activating mechanism); high-dose vitamin E (additive antiplatelet effect); garlic and Ginkgo biloba (additive antiplatelet effect). Severity: caution-level.
  • Interaction with other senolytics and senomorphics: The dasatinib-plus-quercetin (a multi-kinase inhibitor combined with a flavonoid) regimen targets overlapping anti-apoptotic pathways. Combining fisetin with dasatinib-plus-quercetin risks excessive total senolytic dosing and should only be done under medical supervision within a clinical-trial protocol. Mitigating action: space senolytic courses, never combine two high-dose senolytic protocols within the same cycle, and monitor for prolonged inflammatory rebound.
  • Populations to avoid this intervention: Pregnancy and lactation (no safety data); active bleeding disorder or on therapeutic-dose anticoagulation without specialist oversight; scheduled surgery within 7–14 days (discontinue due to antiplatelet potential); severe hepatic impairment (Child-Pugh Class B or C); severe renal impairment (eGFR < 30 mL/min/1.73m²); active malignancy outside a trial protocol; children and adolescents (no pediatric safety or efficacy data). A separate open-label trial of senolytic fisetin is enrolling adult survivors of childhood cancer (NCT04733534) — this is an adult, not pediatric, study. Mitigating actions: for any of the excluded categories, defer senolytic-dose fisetin; low-dose daily fisetin (≤500 mg) is better tolerated but still warrants individualized clinical review.

Risk Mitigation Strategies

  • Take with food containing fat: Consuming fisetin with a meal containing dietary fat reduces GI discomfort and modestly improves absorption, directly mitigating the most common side effect.
  • Low-dose tolerability trial before senolytic course: Beginning with 100–500 mg/day for several days — well below the senolytic 20 mg/kg dose — to assess individual GI and general tolerability mitigates risk of an unpleasant or unmanageable senolytic cycle.
  • Use a bioavailability-enhanced formulation: Galactomannan-fiber or liposomal fisetin formulations improve absorption and can allow lower total doses to achieve the same tissue exposure, reducing GI burden and cost per cycle while maintaining senolytic intent.
  • Space senolytic cycles appropriately: Maintaining at least 28–30 days between high-dose courses mitigates the theoretical risk of impaired tissue repair and allows normal progenitor cells to replace cleared senescent cells.
  • Medication review before dosing: A pre-protocol review of prescription and over-the-counter medications — focused on anticoagulants, CYP3A4 substrates, and CYP2C9 substrates — mitigates drug-drug interaction risk.
  • Baseline and follow-up hepatic and renal monitoring: Baseline ALT, AST, creatinine, and eGFR followed by retest every 3–6 months during ongoing senolytic cycling mitigates risk of unrecognised hepatic or renal stress.
  • Discontinue 7–14 days before any planned surgery: Pausing fisetin in this window mitigates the antiplatelet interaction risk at the point of highest consequence.
  • Avoid stacking with other senolytics outside medical supervision: Avoiding concurrent dasatinib-plus-quercetin or other senolytic agents in the same cycle mitigates the risk of excessive total senolytic load.

Therapeutic Protocol

The most widely studied senolytic fisetin regimen is the intermittent high-dose “hit-and-run” schedule developed by the Kirkland group at Mayo Clinic and used across several human clinical trials. An alternative, much lower-intensity daily maintenance approach is common in consumer and practitioner communities and is not primarily senolytic.

  • Standard senolytic protocol (intermittent high-dose): Approximately 20 mg/kg body weight per day, orally, for 2–3 consecutive days, repeated every 28–30 days. For a 70 kg adult this is approximately 1,400 mg/day; for a 90 kg adult approximately 1,800 mg/day. This is the schedule used in the Mayo Clinic skeletal trial (NCT04313634), the COVFIS-HOME trial (NCT04771611), and the STOP-Sepsis trial (NCT05758246).
  • Alternative daily maintenance protocol: 100–500 mg/day with food. This dosing is better tolerated and more practical for long-term use but is not primarily a senolytic regimen and may act more as a senomorphic, antioxidant, and anti-inflammatory polyphenol than as a true senolytic.
  • Competing approaches — conventional vs. integrative: A conventional, evidence-aligned approach treats fisetin as investigational: it restricts use to enrollment in a registered clinical trial until human efficacy data are available. An integrative-longevity approach treats the preclinical data and the favorable safety profile as sufficient to justify intermittent self-administered use. Neither is the default; the current evidence base supports presenting both and identifying where each is anchored.
  • Expert reference: The hit-and-run schedule was developed by James Kirkland and Tamar Tchkonia at the Mayo Clinic, based on preclinical data showing that brief high-concentration exposure is sufficient to trigger apoptosis in senescent cells, after which the compound can be cleared.
  • Best time of day: No strong time-of-day signal exists in the clinical or preclinical literature. Dosing with the largest fat-containing meal of the day is a common practical choice that may modestly improve absorption and reduce GI symptoms.
  • Half-life: Approximately 1–3 hours for the parent compound in plasma; glucuronide and sulfate metabolites persist longer. The short plasma half-life is part of the mechanistic rationale for the brief-course hit-and-run schedule.
  • Single dose vs. split doses: Published protocols generally use once-daily or twice-daily administration with meals across the 2–3 day dosing window. Split dosing (morning and evening with meals) can reduce peak-related GI symptoms at high total daily intakes.
  • Genetic polymorphisms: CYP3A4 poor-metabolizer status, UGT1A1 variants (including Gilbert syndrome), and COMT slow-metabolizer status may all reduce fisetin clearance and effectively increase exposure at a given dose. ABCB1 variants can shift tissue distribution. Pharmacogenomic-guided dosing is not yet standard but is a plausible direction as human data accumulate.
  • Sex-based differences: Published senolytic trials do not apply sex-based dose adjustments; the 20 mg/kg body-weight schedule is used for all participants.
  • Age-related considerations: Older adults over 75 may benefit from a more conservative initial dose (for example, 15 mg/kg rather than 20 mg/kg) and a longer inter-cycle interval (for example, every 6 weeks rather than 4) to accommodate reduced hepatic and renal clearance.
  • Baseline biomarker levels: Elevated hs-CRP (above approximately 1.0 mg/L on a functional scale, above 3.0 mg/L conventionally) or elevated IL-6 (above approximately 3.0 pg/mL) identify adults in whom a measurable SASP-reduction signal is most likely to be detectable on re-test.
  • Pre-existing health conditions: Moderate hepatic impairment warrants dose reduction and closer hepatic monitoring. Osteoarthritis, idiopathic pulmonary fibrosis, and chronic kidney disease are populations in which active clinical trials are enrolling and in which senolytic fisetin is most plausibly beneficial.

Discontinuation & Cycling

  • Lifelong vs. short-term: The hit-and-run protocol is intrinsically intermittent rather than continuous. No fixed total-duration endpoint has been established; common longevity-practitioner framing treats it as an ongoing strategy with periodic reassessment — typically every 6–12 months — based on biomarker response and tolerability.
  • Withdrawal effects: No withdrawal syndrome has been reported with fisetin discontinuation. Because fisetin has a short plasma half-life, no known receptor dependence, and no physiological tolerance profile, abrupt cessation is not expected to cause rebound.
  • Tapering-off protocol: No tapering is required. The intermittent dosing structure already incorporates extended drug-free intervals, so fisetin can be stopped at any time without a taper schedule.
  • Cycling for efficacy: Cycling is intrinsic to the senolytic rationale. The 28–30 day inter-course interval allows time for immune clearance of apoptotic debris and for progenitor cells to replace eliminated senescent cells. Dosing more frequently has no demonstrated efficacy benefit and may interfere with regenerative tissue processes.

Sourcing and Quality

  • Source material: Commercial fisetin is typically extracted from Cotinus coggygria (smoke tree) or Rhus succedanea (wax tree) heartwood, not from dietary sources — strawberries, the richest dietary source, contain only on the order of 160 μg/g, far below what is needed for therapeutic dosing. Synthetic fisetin is also commercially available and can offer higher purity.
  • Purity: A reputable product is standardised to ≥98% fisetin with a lot-specific Certificate of Analysis from an independent laboratory. Lower-purity extracts may contain other flavonoids (e.g., quercetin, kaempferol) that alter the effect profile.
  • Bioavailability-enhanced formulations: Given fisetin’s poor native bioavailability, formulations designed to improve absorption are worth prioritising. Galactomannan-based fisetin (e.g., Life Extension Bio-Fisetin) has demonstrated approximately 25-fold increased bioavailability in a human pharmacokinetic study (Krishnakumar et al., 2022; PMID 36304817). Liposomal fisetin formulations are also available.
  • Reputable brands: Brands that publish lot-specific Certificates of Analysis, use Good Manufacturing Practice (GMP)-certified facilities, and rely on third-party testing include Life Extension (Bio-Fisetin), Doctor’s Best, Toniiq, Double Wood Supplements, and OMRE. Compounding pharmacies are less commonly used for fisetin because it is a non-prescription flavonoid.
  • Third-party testing: Certification from NSF International, USP (United States Pharmacopeia), or an ISO 17025-accredited independent laboratory confirms identity, assay, and absence of heavy-metal, pesticide, and microbial contamination.

Practical Considerations

  • Time to effect: Measurable biomarker changes — reductions in hs-CRP, IL-6, and other SASP-associated cytokines — may be detectable within days to weeks of a single senolytic cycle. Subjective changes such as reduced joint stiffness or improved energy typically take 2–4 monthly cycles to become noticeable, if they do.
  • Common pitfalls: Chronic low-dose daily use (100–200 mg) mistaken for a senolytic regimen; use of unformulated low-bioavailability fisetin at doses that never reach senolytic tissue exposure; stacking with dasatinib-plus-quercetin or other senolytics without medical oversight; expecting rapid subjective effects and abandoning the protocol after one cycle; not establishing baseline biomarkers, which makes any subsequent change uninterpretable.
  • Regulatory status: Fisetin is sold as a dietary supplement in the United States under the Dietary Supplement Health and Education Act of 1994 and is not US Food and Drug Administration (FDA)-approved for any medical indication. It is generally recognised as safe (GRAS) as a naturally occurring dietary flavonoid. Clinical trials in humans are conducted under Investigational New Drug (IND) protocols for specific indications.
  • Cost and accessibility: Standard 100–500 mg capsules typically cost $15–$40 for a 30–60 day supply. Bioavailability-enhanced formulations are somewhat more expensive, typically $25–$50 for a 30-count supply. A single senolytic cycle at 20 mg/kg for 2–3 days can require 15–20 capsules of a 500 mg product and is the main cost driver; because cycles are monthly, per-year cost remains moderate compared with prescription senolytics.

Interaction with Foundational Habits

  • Sleep: Fisetin does not have a known direct effect on sleep architecture, and no insomnia signal has been reported in clinical trials. Indirect potentiating effect: sustained reduction in systemic inflammation through senolytic cycling may, over months, improve sleep quality in adults with inflammation-driven sleep disruption. No specific dosing-time constraint around sleep is established.
  • Nutrition: Absorption is improved by co-administration with a fat-containing meal — a direct, practically relevant interaction. A broader anti-inflammatory dietary pattern (vegetables, berries, omega-3-rich foods, olive oil) may potentiate fisetin’s anti-inflammatory effects. Fisetin is not known to deplete any specific nutrient.
  • Exercise: Exercise itself has mild senolytic and anti-inflammatory effects, so the interaction with fisetin is best described as potentially potentiating. Unlike high-dose vitamin C and E, fisetin has not been shown to blunt training adaptations or hypertrophy, and there is no established need to time dosing around workouts.
  • Stress management: Chronic psychological stress accelerates cellular senescence through elevated inflammatory signalling and glucocorticoid exposure, so stress management is biologically synergistic with senolytic therapy. Fisetin does not directly modulate cortisol or the HPA (hypothalamic-pituitary-adrenal, the body’s central stress response) axis; the interaction is indirect, via reduced baseline inflammation.

Monitoring Protocol & Defining Success

Baseline labs are obtained before the first senolytic cycle, with follow-up testing at 3-month and 6-month intervals during ongoing cycling. The monitoring strategy has three objectives: (1) confirm safety (hepatic, renal, hematologic), (2) detect a SASP-reduction signal, and (3) track longitudinal age- and senescence-associated biomarkers.

Ongoing monitoring cadence: hepatic and renal labs at baseline, 1–2 weeks after the first senolytic cycle, and then every 3–6 months during continued cycling. Inflammation and senescence biomarkers at baseline and every 3 months for the first year, then every 6–12 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
hs-CRP < 1.0 mg/L (optimal < 0.5 mg/L) Tracks systemic inflammation and SASP reduction hs-CRP = high-sensitivity C-reactive protein; conventional upper reference ~3.0 mg/L; fasting not required; most accessible SASP-adjacent marker
IL-6 < 1.0 pg/mL Direct SASP cytokine; most specific senescence-adjacent serum marker IL-6 = interleukin-6; conventional upper reference ~1.8 pg/mL; fasting preferred; not available in all reference labs
TNF-α < 2.5 pg/mL Key SASP cytokine; complements IL-6 TNF-α = tumor necrosis factor-alpha; assay variability is significant; best used longitudinally in the same lab
GDF-15 < 1,200 pg/mL Emerging aging and cellular-stress biomarker GDF-15 = growth differentiation factor 15; rises with age and in metabolic disease; specialty labs only; useful for longitudinal tracking
p16INK4a Age-adjusted reference Cell-intrinsic senescence marker p16INK4a = cyclin-dependent kinase inhibitor 2A, assayed in peripheral T cells; research-grade assay; not yet widely clinically available
ALT 10–25 U/L (male), 10–20 U/L (female) Hepatic safety during high-dose protocol ALT = alanine aminotransferase; conventional upper reference ~40 U/L; check at baseline and 1–2 weeks after first senolytic cycle
AST 10–25 U/L Hepatic safety; complements ALT AST = aspartate aminotransferase; best interpreted together with ALT
Creatinine / eGFR Creatinine 0.7–1.2 mg/dL; eGFR > 90 mL/min/1.73m² Renal safety monitoring eGFR = estimated glomerular filtration rate; conventional eGFR cutoff > 60; functional optimal > 90; check at baseline and every 6 months
CBC with differential Age-appropriate ranges Monitor for unexpected hematologic changes after senolytic cycling CBC = complete blood count; lymphocyte and monocyte subsets may shift briefly post-course
Fasting glucose 72–85 mg/dL Metabolic health and insulin sensitivity Conventional upper reference < 100 mg/dL; 12-hour fast required
HbA1c < 5.3% 3-month average glycemic control HbA1c = glycated hemoglobin; conventional target < 5.7%; functional optimal < 5.3%
Advanced lipid panel LDL-P < 1,000 nmol/L; triglycerides < 100 mg/dL Cardiovascular risk profile LDL-P = low-density lipoprotein particle number; 12-hour fast required; Lp(a) once at baseline
Coagulation panel (PT/INR, aPTT) Within-reference Baseline assessment before high-dose protocol PT/INR = prothrombin time / international normalized ratio; aPTT = activated partial thromboplastin time; particularly important for adults on antiplatelet or anticoagulant therapy

Qualitative markers to track alongside labs:

  • Joint comfort and mobility (e.g., morning stiffness duration, ability to perform loaded exercise without pain)
  • Perceived energy and fatigue over the day
  • Exercise recovery time between sessions
  • Cognitive clarity, focus duration, and subjective memory
  • General sense of vitality and resilience to minor illness

Emerging Research

The clinical-trial landscape for senolytic fisetin has expanded substantially since 2018 and is currently one of the most active areas in translational geroscience.

  • Landmark preclinical references: The foundational senolytic paper remains Yousefzadeh et al. 2018 (PMID 30279143). The negative Interventions Testing Program replication in UM-HET3 mice is reported in Harrison et al. 2023 (PMID 38041783). A comprehensive 2024 narrative review by Tavenier et al. (PMID 39384074) surveys the evidence and the discrepancies.
  • Completed or reported human trials: The COVFIS-HOME trial (NCT04771611) evaluated fisetin 20 mg/kg for 2 days in 55 older COVID-19 outpatients, with safety, tolerability, and SASP-marker endpoints. A Mayo Clinic Phase 2 trial of senolytics for skeletal health in older adults (NCT04313634) has completed enrollment of approximately 74 participants with bone-metabolism and senescence-marker endpoints.
  • Actively recruiting trials: STOP-Sepsis (NCT05758246) is a multicentre Phase 2 randomised trial of fisetin 20 mg/kg/day for 3 days in approximately 220 older adults with sepsis, the largest fisetin senolytic trial to date. Additional Phase 1/2 trials are evaluating fisetin in peripheral arterial disease (a circulatory condition in which narrowed leg arteries reduce blood flow) (NCT06399809, approximately 34 participants), a pharmacokinetics-and-safety multimorbidity study (NCT06431932, approximately 60 participants), and a combination oncology trial of fisetin with dasatinib, quercetin, and temozolomide in previously treated glioma (NCT07025226).
  • Active but not recruiting: A Phase 1/2 trial of fisetin for vascular function in older adults (NCT06133634, approximately 70 participants) with endothelial-function and arterial-stiffness endpoints. An open-label trial of fisetin in adult survivors of childhood cancer (NCT04733534, approximately 110 participants) targets accelerated senescence and frailty in a population with documented age-associated phenotypes.
  • Future research directions that could strengthen the case: Bioavailability-enhanced formulations — galactomannan-based, liposomal, nanoparticle, and hybrid hydrogel delivery — may address the core limitation of oral fisetin. A 2023 formulation review by Szymczak and Cielecka-Piontek (PMID 37762460) summarises the current pharmaceutical-technology pipeline. Combination senolytic trials (fisetin with quercetin or with dasatinib-plus-quercetin) under medical supervision may achieve synergistic clearance at lower individual doses.
  • Future research directions that could weaken the case: Additional independent high-rigor rodent lifespan studies that fail to find a signal would further erode the translational rationale. Human trials showing no reduction in SASP markers after short-course senolytic fisetin, or no functional benefit in populations with documented senescence burden, would reposition fisetin as primarily an anti-inflammatory flavonoid rather than a true senolytic.

Conclusion

Fisetin is an interesting but still early-stage candidate senolytic. Preclinical work positions it as one of the most active flavonoids for clearing senescent cells, supports a tentative lifespan signal in aged mice, and grounds a coherent mechanistic rationale — selective induction of apoptosis in senescent cells via anti-apoptotic-protein inhibition, coupled with direct anti-inflammatory and antioxidant activity. That early enthusiasm has been tempered by a rigorous multi-site rodent replication effort that did not find a lifespan effect, and by the lack of completed large human efficacy trials.

The evidence base presents a coherent, if incomplete, picture: robust preclinical support for senolytic, anti-inflammatory, antioxidant, and neuroprotective activity; a well-defined intermittent high-dose protocol that is the most-studied approach in humans; a manageable side-effect profile dominated by transient gastrointestinal symptoms; a meaningful limitation in native oral bioavailability that modern formulations partially address; and an expanding pipeline of human trials. The intervention is inexpensive, widely available as a dietary supplement, and not subject to prescription-access barriers. Much of the foundational positive evidence traces to the Mayo Clinic/University of Minnesota senolytic program, whose institutional and grant-funding commitments to senolytic development represent a structural conflict of interest that should be weighed alongside the data.

An honest summary is that the direction of the preclinical evidence is promising and the translational gap to humans is real and unresolved, with the field currently sitting between “promising senolytic” and “useful anti-inflammatory polyphenol” without a decisive resolution.

Top - Benefits - Risks - Protocol